Notes to the Financial Statements Note 2: Revenue and Expenses continued The table summarises the Group's operating revenue by product or service category: Revenue 2026 2025 US$m US$m CSL Behring Immunoglobulins 6,248 6,064 Albumin 1,115 1,297 Haemophilia 1,515 1,488 Hereditary Angioedema 884 760 Peri-Operative Bleeding 834 913 Other 754 598 CSL Vifor Nephrology - Non-Dialysis 330 267 Nephrology - Dialysis 1,036 871 Iron 915 1,034 Other 75 53 CSL Seqirus Adjuvanted egg based vaccines 968 901 Cell culture vaccines 503 474 Egg based vaccines 107 116 Pandemic reservation fees 183 179 Pre pandemic sales 61 197 Other (including in-license) 170 218 Total revenue from contracts with customers 15,698 15,430 Other income 99 128 Total operating revenue 15,797 15,558 Recognition and measurement of expenses The table summarises certain Group expenses (excluding impairment detailed in Note 3) by category: Expenses 2026 2025 US$m US$m Borrowing costs 377 389 Lease interest expense 53 55 Fair value losses on financial assets 5 4 Total finance costs 435 448 Depreciation of property, plant and equipment (PPE) and right-of-use assets (Note 9) 555 549 Amortisation of acquired intellectual property (IP) (Note 8) 379 364 Amortisation of other intangibles (excluding acquired IP) (Note 8) 107 104 Total depreciation and amortisation expense 1,041 1,017 Write-down of inventory 294 163 Employee benefits expense 4,052 3,855 Foreign exchange losses 17 55 Expenses include finance costs which represents interest expense and borrowing costs. Costs are recognised as an expense when incurred, except where finance costs are directly attributable to the acquisition or construction of a qualifying asset where they are capitalised as part of the cost of the asset. Capitalised interest for qualifying assets during the year ended 30 June 2026 is $54m (2025: $68m). Any difference between borrowing proceeds (net of transaction costs) and the redemption value is recognised in the statement of comprehensive income using the effective interest rate method. Fair value losses on financial assets primarily relates to the Group's investments in venture funds measured at fair value through the profit or loss (Note 11(e)). The resulting changes in fair value are recognised directly to the profit or loss within finance costs at each reporting period. Foreign exchange gains and losses are recorded net within administration expenses in the statement of comprehensive income. 98 98 Financial Report
RkJQdWJsaXNoZXIy MjE2NDg3